DAHUA-TECHNOLOGY
10.8.2021 15:47:09 CEST | Business Wire | Press release
Dahua Technology, a world leading video-centric smart IoT solution and service provider, has recently released its upgraded Full-color 2.0 Network Cameras that offer brand new functions – including Dual-lens, 4K Color Image, Vari-focal Lens, and AI Features – that can significantly optimize surveillance monitoring and greatly benefit end users in terms of clear and colorful image output.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005584/en/
Dual-lens Camera
The upgraded Full-color 2.0 offers dual-lens cameras with large F1.0 aperture, and Dual Light Fusion technology that collects visible color details and lightness information using separate lenses. Equipped with dual CMOS (1/1.8” and 1/2.8”), these cameras provide 36% increase in brightness and 14 times increase in s/n ratio. With pixel-level frame-by-frame mapping, they present high image definition and vivid colors even when the supplementary white light is off, thus reducing light pollution and attraction of insects. Also, its high precision AA (Active Alignment) process ensures that the lenses and sensors are all precisely aligned, allowing it to capture clear color images.
4K Color Image
The 4K network cameras of Full-color 2.0 are equipped with 1/1.2” image sensor. Compared with conventional 8MP camera, this image sensor significantly increases the pixel size by 110%, allowing it to capture real-time 4K color images even under low-light condition. These cameras also boast 42% increase in brightness, and 400% increase in S/N Ratio, providing a clear and high-quality image of the monitored scene.
Vari-focal Lens
The Full-color 2.0 cameras with vari-focal lens offer approx. 5x optical zoom and auto focus function that can maintain clear details even after zooming in. It solves the difficulty in capturing vivid color details of targets during night time or in environments with low illumination, which is a common pain point when using traditional IR vari-focal cameras. It covers narrow indoor spaces and wide outdoor scenarios, which can help ease operation and save time and labor costs.
AI Features
The upgraded Full-color 2.0 network cameras can work with Dahua 5-I/L series NVR, which enables color search for human and vehicle targets (person’s clothes and car exterior) and allows extraction of relevant video footages. It also offers AI Schedule that allows users to set different AI functions according to the time schedule.
By releasing its upgraded Full-color 2.0 Network Cameras, Dahua Technology delivers another artillery of new technologies that can enhance conventional monitoring and meet the various requirements of its customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005584/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
